Zdrowie i gospodarka · 23/06/2015

FDA Clears ABILIFY Solution for Continued Sale Amidst Safety and Effectiveness Review

The US Food and Drug Administration (FDA) has concluded that the ABILIFY (Aripiprazole) Solution was not withdrawn from the market due to concerns over its safety or efficacy, allowing the agency to continue reviewing abbreviated new drug applications (ANDAs) related to the product.